Drugs / CX2101A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06864182 | Mar → May 2024 | COVID-19 | Heronova Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06860282 | Dec 2022 → Mar 2023 | COVID-19, viral pneumonia | Heronova Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX2101A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06864182 ↗ |
| Route | Oral | “Participants received single dose of CX2101A orally. Dose levels are 20 mg, 80 mg, 160 mg, 300 mg and 600 mg.” NCT06860282 ↗ |